Early trial tests Double-Drug attack on tough skin cancer
NCT ID NCT03021460
Summary
This early-stage study is testing the safety and best dose of a new drug combination for advanced melanoma that has spread or cannot be surgically removed. It combines pembrolizumab, an immunotherapy drug, with ibrutinib, a drug that may block cancer cell growth. The goal is to see if using these two drugs together is safe and more effective than current treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III CUTANEOUS MELANOMA AJCC V7 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.